SERES Therapeutics, Inc.

Posted on May 12, 2016 — Kat Hinkel

PCI negotiated a multi-year collaboration with Seres Therapeutics, Inc. a leading microbiome therapeutics platform company to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disease (IBD). Under the terms of the agreement, Penn Professors Gary D. Wu, M.D., and James Lewis, M.D., two global…

Dimension Therapeutics

Posted on May 6, 2016 — Kat Hinkel

PCI facilitated a new research collaboration between Dimension Therapeutics and Penn Medicine to advance certain gene therapies for inherited metabolic diseases.  Dimension’s collaboration will focus on research conducted with Dr. James Wilsonand  will include programs designed to treat citrullinemia type 1, phenylketonuria (PKU), and Wilson disease, a rare genetic disease associated with the liver that…